Prime Medicine prices $125M stock offering at $3.50/share
Cambridge, Massachusetts - Prime Medicine Inc. announced the pricing of a public offering for its common stock on Tuesday. The company sold 35.7 million shares at $3.50 per share, raising an estimated $125 million in gross proceeds before fees. Underwriters were given the option to purchase an additional 5.4 million shares over a 30-day period.
The offering is set to close by November 12, 2026, pending usual closing conditions. Prime Medicine, a biotechnology firm, is utilizing its Prime Editing platform to develop therapies for liver, lung, immunology, and oncology conditions. The shares were issued pursuant to a shelf registration statement filed with the SEC on November 7, 2025, and became effective on March 4, 2026.
Investment banks Jefferies, TD Cowen, and Goldman Sachs & Co. acted as the lead managers, with Oppenheimer & Co. and LifeSci Capital serving as passive managers.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
